HomeCompareORXOF vs PLD

ORXOF vs PLD: Dividend Comparison 2026

ORXOF yields 87.48% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $3.61M in total portfolio value· pulled ahead in Year 10
10 years
ORXOF
ORXOF
● Live price
87.48%
Share price
$2.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.30M
Annual income
$708,964.09
Full ORXOF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ORXOF vs PLD

📍 PLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOF
Annual income on $10K today (after 15% tax)
$7,435.92/yr
After 10yr DRIP, annual income (after tax)
$602,619.48/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,435,496.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOF + PLD for your $10,000?

ORXOF: 50%PLD: 50%
100% PLD50/50100% ORXOF
Portfolio after 10yr
$4.11M
Annual income
$2,729,844.64/yr
Blended yield
66.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ORXOF
No analyst data
Altman Z
-0.2
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOF buys
0
PLD buys
13
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$PLD▼ Sell$1,001 - $15,0002026-02-26
David Taylor🏢 House$PLD▲ Buy$1,001 - $15,0002026-01-29
David Taylor🏢 House$PLD▼ Sell$1,001 - $15,0002026-01-16
Ro Khanna🏢 House$PLD▲ Buy$1,001 - $15,0002025-08-26
Dan Newhouse🏢 House$PLD▲ Buy$1,001 - $15,0002025-08-18
David Taylor🏢 House$PLD▲ Buy$1,001 - $15,0002025-08-14
David Taylor🏢 House$PLD▲ Buy$1,001 - $15,0002025-08-07
Shelley Moore Capito🏛 Senate$PLD▲ Buy$1,001 - $15,0002025-08-01
Shelley Moore Capito🏛 Senate$PLD▲ Buy$1,001 - $15,0002025-08-01
Thomas H. Kean🏢 House$PLD▲ Buy$1,001 - $15,0002025-06-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOFPLD
Forward yield87.48%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$2.30M$5.91M
Annual income after 10y$708,964.09$4,750,725.19
Total dividends collected$2.02M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ORXOF vs PLD ($10,000, DRIP)

YearORXOF PortfolioORXOF Income/yrPLD PortfolioPLD Income/yrGap
1$19,448$8,748.14$11,241$540.96+$8.2KORXOF
2$36,710$15,900.47$13,019$991.13+$23.7KORXOF
3$67,330$28,049.97$15,801$1,870.97+$51.5KORXOF
4$120,123$48,080.71$20,609$3,701.21+$99.5KORXOF
5$208,701$80,169.36$29,919$7,867.97+$178.8KORXOF
6$353,484$130,173.43$50,631$18,617.74+$302.9KORXOF
7$584,283$206,054.85$105,528$51,352.20+$478.8KORXOF
8$943,494$318,311.52$287,364$174,449.42+$656.1KORXOF
9$1,489,918$480,379.75$1,081,760$774,280.77+$408.2KORXOF
10← crossover$2,303,177$708,964.09$5,908,209$4,750,725.19$3.61MPLD

ORXOF vs PLD: Complete Analysis 2026

ORXOFStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ORXOF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOF vs SCHDORXOF vs JEPIORXOF vs OORXOF vs KOORXOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.